Literature DB >> 10797166

Ischemic stroke subtypes : a population-based study of functional outcome, survival, and recurrence.

G W Petty1, R D Brown, J P Whisnant, J D Sicks, W M O'Fallon, D O Wiebers.   

Abstract

BACKGROUND AND
PURPOSE: There is scant population-based information on functional outcome, survival, and recurrence for ischemic stroke subtypes.
METHODS: We identified all residents of Rochester, Minnesota, with a first ischemic stroke from 1985 through 1989 using the resources of the Rochester Epidemiology Project medical records linkage system. After reviewing medical records and imaging studies, we assigned patients to 4 major ischemic stroke categories based on National Institute of Neurological Diseases and Stroke Data Bank criteria: large-vessel cervical or intracranial atherosclerosis with stenosis (ATH, n=74), cardioembolic (CE, n=132), lacunar (LAC, n=72), and infarct of uncertain cause (IUC, n=164). We used the Rankin disability score to assess functional outcome and the Kaplan-Meier product-limit method and Cox proportional hazards regression analysis with bootstrap validation to estimate rates and identify predictors of survival and recurrent stroke among these patients.
RESULTS: Rankin disabilities were different across stroke subtypes at the time of stroke and 3 months and 1 year later (P=0.001). LAC was associated with milder deficits compared with other subtypes. Mean follow-up among the 442 patients in the cohort was 3.2 years. Estimated rates of recurrent stroke at 30 days were significantly different (P<0.001): ATH, 18.5% (95% CI 9.4% to 27.5%); CE, 5.3% (95% CI 1.2% to 9.6%); LAC, 1.4% (95% CI 0.0% to 4.1%); and IUC, 3. 3% (95% CI 0.4% to 6.2%). After adjusting for age, sex, and stroke severity, infarct subtype was an independent determinant of recurrent stroke within 30 days (P=0.0006; eg, risk ratio for ATH compared with CE=3.3, 95% CI 1.2 to 9.3) but not long term (P=0.07). Four of 25 recurrent strokes within 30 days were procedure-related, each in patients with ATH. Five-year death rates were significantly different (P<0.001): ATH, 32.2% (95% CI 21.1% to 43.2%); CE, 80.4% (95% CI 73.1% to 87.6%); LAC, 35.1% (95% CI 23.6% to 46.0%); and IUC, 48.6% (95% CI 40.5% to 56.7%). With adjustment for age, sex, cardiac comorbidity, and stroke severity, the subtype of ischemic stroke was an independent determinant of long-term (P=0.018; eg, risk ratio for ATH compared with cardioembolic=0.47, 95% CI 0.29 to 0.77) but not 30-day survival (P=0.2).
CONCLUSIONS: Early recurrence rates for ischemic stroke caused by ATH are higher than those for other subtypes and higher than previous non-population-based studies have reported. Some of the increased risk of early recurrence among patients with ATH may be iatrogenic. Patients with LAC have better poststroke functional status than those with other subtypes. Survival is poorest among those with ischemic stroke with a cardiac source of embolism.

Entities:  

Mesh:

Year:  2000        PMID: 10797166     DOI: 10.1161/01.str.31.5.1062

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  151 in total

1.  The prognostic factors that influence long-term survival in acute large cerebral infarction.

Authors:  Sung Yun Cho; Chang Wan Oh; Hee-Joon Bae; Moon-Ku Han; Hyun Park; Jae Seung Bang
Journal:  J Korean Neurosurg Soc       Date:  2011-02-28

2.  The action of dipyridamole to prevent thrombosis: practical implications for the treatment and prevention of stroke.

Authors:  Christopher D Booze; Victor L Serebruany
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-05

3.  Risk factors for and incidence of subtypes of ischemic stroke.

Authors:  Hege Ihle-Hansen; Bente Thommessen; Torgeir Bruun Wyller; Knut Engedal; Brynjar Fure
Journal:  Funct Neurol       Date:  2012 Jan-Mar

4.  Patent foramen ovale and stroke: Should PFOs be closed in otherwise cryptogenic stroke?

Authors:  David A Carpenter; Andria L Ford; Jin-Moo Lee
Journal:  Curr Atheroscler Rep       Date:  2010-07       Impact factor: 5.113

5.  Organized Comprehensive Stroke Center is Associated with Reduced Mortality: Analysis of Consecutive Patients in a Single Hospital.

Authors:  Dae-Hyun Kim; Jae-Kwan Cha; Hyo-Jin Bae; Hyun-Seok Park; Jae-Hyung Choi; Myung-Jin Kang; Byoung-Gwon Kim; Jae-Taeck Huh; Sang-Beom Kim
Journal:  J Stroke       Date:  2013-01-31       Impact factor: 6.967

6.  C-reactive protein as a prognostic marker after lacunar stroke: levels of inflammatory markers in the treatment of stroke study.

Authors:  Mitchell S V Elkind; Jorge M Luna; Leslie A McClure; Yu Zhang; Christopher S Coffey; Ana Roldan; Oscar H Del Brutto; Edwin Javier Pretell; L Creed Pettigrew; Brett C Meyer; Jorge Tapia; Carole White; Oscar R Benavente
Journal:  Stroke       Date:  2014-02-12       Impact factor: 7.914

7.  Achieving low density lipoprotein-cholesterol<70mg/dL may be associated with a trend of reduced progression of carotid artery atherosclerosis in ischemic stroke patients.

Authors:  Qian Zhang; Shimeng Liu; Yumei Liu; Yang Hua; Haiqing Song; Yi Ren; Yang Song; Ran Liu; Wuwei Feng; Bruce Ovbiagele; Jianping Ding; Xunming Ji
Journal:  J Neurol Sci       Date:  2017-04-17       Impact factor: 3.181

8.  Risk Factors, Clinical Features and Prognosis for Subtypes of Ischemic Stroke in a Chinese Population.

Authors:  Ya-Fu Tan; Li-Xuan Zhan; Xiao-Hui Chen; Jian-Jun Guo; Chao Qin; En Xu
Journal:  Curr Med Sci       Date:  2018-04-30

9.  Specific DWI lesion patterns predict prognosis after acute ischaemic stroke within the MCA territory.

Authors:  O Y Bang; P H Lee; K G Heo; U S Joo; S R Yoon; S Y Kim
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

10.  Albumin-Induced Neuroprotection in Focal Cerebral Ischemia in the ALIAS Trial: Does Severity, Mechanism, and Time of Infusion Matter?

Authors:  Rakesh Khatri; Mohammad Rauf Afzal; Gustavo J Rodriguez; Alberto Maud; Muhammad Shah Miran; Mohtashim Arbaab Qureshi; Salvador Cruz-Flores; Adnan I Qureshi
Journal:  Neurocrit Care       Date:  2018-02       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.